Skip to content

US · ALVO · DRUG MANUFACTURERS - SPECIALTY & GENERIC

Alvotech (ALVO) intrinsic value and stock valuation

$4.12as of 2026-11-21 · Mkt cap 1.27B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Alvotech DCF and intrinsic value

InvestorsCraft values ALVO with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from ALVO’s statements →

Alvotech Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Drug Manufacturers - Specialty & Generic Luxembourg, LU L-1273 alvotech.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$586.3M+54.5% 5y CAGRd
20192025
Net income
$27.9M
20192025
Free cash flow
-$-114.67M
20192025
Total equity
-$-284.49M
20202025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$586.3M$489.7M$91.4M$83M$36.8M
Operating income$78.2M$69.6M-$-354.86M-$-346.44M-$-235.46M
Net income$27.9M-$-231.86M-$-551.73M-$-513.58M-$-101.5M
EPSd$100K-$-865.41K-$-2.43M-$-2.6M-$-3.25M
Operating cash flow-$-50.2M-$-236.84M-$-312.19M-$-312.39M-$-228.17M
Capital expenditure-$-64.47M-$-57M-$-46.47M-$-49M-$-40.63M
Free cash flow-$-114.67M-$-293.84M-$-358.66M-$-361.39M-$-268.8M
Total assets$1.49B$1.22B$950.1M$828.4M$598M
Total debt$1.45B$1.19B$1.08B$805.1M$523.1M
Net debt$1.28B$1.14B$1.06B$738.7M$505.5M
Total equity-$-284.49M-$-412.77M-$-932.49M-$-564.42M-$-135.61M
Cash and short-term investments$172.4M$51.4M$11.2M$66.4M$17.6M
Income statement
20252024202320222021
Revenue$586.3M$489.7M$91.4M$83M$36.8M
Cost of revenue$235.6M$185.3M$160.9M$64.1M$0.00
Gross profit$350.8M$304.4M-$-69.42M$18.9M$36.8M
Research and development expenses$184.2M$171.3M$210.8M$180.6M$191M
Selling, general and administrative expenses$91M$61.5M$73M$186.7M$84.1M
Other expenses-$-2.58M$1.96M$1.57M-$-1.99M-$-2.91M
Operating expenses$272.6M$234.7M$285.4M$365.4M$272.2M
Cost and expenses$508.1M$420M$446.3M$429.5M$272.2M
Interest income$198.5M$4.62M$4.82M$910K$20K
Interest expense$149.2M$157.6M$134.8M$91.4M$113M
Depreciation and amortization$37.9M$31.3M$24.2M$20.4M$18.2M
Ebitda$323.4M-$-32.27M-$-493.67M-$-439.8M-$-18.03M
Operating income$78.2M$69.6M-$-354.86M-$-346.44M-$-235.46M
Total other income/expenses, net$58.1M-$-287.21M-$-296.19M-$-205.21M$86.3M
Income before tax$136.4M-$-217.56M-$-651.05M-$-551.65M-$-149.2M
Income tax expense$108.4M$14.3M-$-99.32M-$-38.07M-$-47.69M
Net income$27.9M-$-231.86M-$-551.73M-$-513.58M-$-101.5M
Weighted average shares outstanding$279.2M$267.9M$227.3M$197.7M$31.3M
Weighted average diluted shares outstanding$279.2M$267.9M$227.3M$197.7M$31.3M
Balance sheet
20252024202320222021
Cash and short-term investments$172.4M$51.4M$11.2M$66.4M$17.6M
Net receivables$153.8M$251.7M$87.2M$71.4M$53.9M
Inventory$220.1M$127.9M$74.4M$71.5M$39.1M
Total current assets$574M$455M$194.8M$230.7M$119.8M
Property, plant and equipment, net$356.4M$409.7M$356.6M$268.1M$205.3M
Goodwill and intangible assets$94.7M$32M$31.1M$37.3M$33.9M
Long-term investments$122.9M$22.7M$18.5M$48.6M$55.3M
Total non-current assets$913.1M$766.4M$755.3M$597.7M$478.2M
Total assets$1.49B$1.22B$950.1M$828.4M$598M
Accounts payable$126.1M$67.1M$80.6M$49.2M$28.6M
Short-term debt$49M$42.2M$47.7M$25.1M$10.1M
Deferred revenue$30.4M$16M$59.2M$36.9M$29.7M
Total current liabilities$304.1M$193.4M$261M$167.3M$111.8M
Long-term debt$1.4B$1.15B$1.03B$780M$513M
Deferred revenue, non-current$5.5M$80.7M$73.3M$57M$44.8M
Total non-current liabilities$1.47B$1.44B$1.62B$1.23B$621.8M
Capital lease obligations$150.1M$121.7M$115.3M$40.5M$122.1M
Total liabilities$1.77B$1.63B$1.88B$1.39B$733.6M
Common stock$2.93M$2.83M$2.28M$2.13M$140K
Retained earnings-$-2.41B-$-2.44B-$-2.21B-$-1.65B-$-1.14B
Accumulated other comprehensive income (loss)$16.7M$15.1M$41.4M$29.1M$4.67M
Total equity-$-284.49M-$-412.77M-$-932.49M-$-564.42M-$-135.61M
Total investments$122.9M$22.7M$18.5M$48.6M$55.3M
Total debt$1.45B$1.19B$1.08B$805.1M$523.1M
Net debt$1.28B$1.14B$1.06B$738.7M$505.5M
Cash flow statement
20252024202320222021
Net income$27.9M-$-231.86M-$-551.73M-$-513.58M-$-101.5M
Depreciation and amortization$37.9M$31.3M$24.2M$20.4M$18.2M
Stock-based compensation$17.4M$7.63M$18M$10.3M$0.00
Change in working capital-$-117.64M-$-288.64M$26.3M-$-47.89M-$-6.81M
Accounts receivable-$-6.33M-$-164.24M-$-24.83M-$-13.23M-$-13.53M
Inventory-$-90.13M-$-49.97M-$-11.3M-$-32.41M-$-29.41M
Accounts payable-$-21.18M$0.00$0.00$0.00$14.3M
Net cash provided by operating activities-$-50.2M-$-236.84M-$-312.19M-$-312.39M-$-228.17M
Investments in property, plant and equipment-$-64.47M-$-53.66M-$-33.23M-$-37.88M-$-20.46M
Acquisitions, net-$-14.04M$12M$0.00$0.00$0.00
Net cash used for investing activities-$-104.22M-$-18.87M-$-46.34M-$-63.54M-$-40.63M
Common stock issued$78.7M$150.5M$136.9M$9.83M$185.9M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$270.8M$297.3M$301.3M$424.9M$254.8M
Net change in cash$120.9M$40.3M-$-55.27M$48.9M-$-14.13M
Cash at end of period$172.4M$51.4M$11.2M$66.4M$17.6M
Operating cash flow-$-50.2M-$-236.84M-$-312.19M-$-312.39M-$-228.17M
Capital expenditure-$-64.47M-$-57M-$-46.47M-$-49M-$-40.63M
Free cash flow-$-114.67M-$-293.84M-$-358.66M-$-361.39M-$-268.8M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Alvotech

        Alvotech, along with its various subsidiaries, is dedicated to the global development and manufacturing of biosimilar pharmaceuticals. Its product offerings span key therapeutic categories, encompassing autoimmune conditions, eye disorders, bone diseases, and cancer. A flagship program for the company is AVT02, a high-concentration biosimilar equivalent to Humira. This candidate is designed to address a range of inflammatory illnesses, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. Similarly, AVT04 is a biosimilar version of Stelara, targeting inflammatory conditions such as psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. For ophthalmic conditions, AVT06 serves as a biosimilar to Eylea, intended for the treatment of age-related macular degeneration, macular edema, and diabetic retinopathy. Currently in preclinical stages, AVT03 is a biosimilar to Xgeva and Prolia, with the goal of preventing bone fractures, alleviating spinal cord compression, reducing the necessity for radiation or bone surgery in certain cancer patients, and both preventing bone loss and increasing bone density. Additionally, Alvotech's pipeline features AVT05, an early-stage biosimilar for Simponi and Simponi Aria, which is being developed for various inflammatory conditions like rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Other promising candidates include AVT16, an immunology biosimilar; AVT23, a late-stage biosimilar to Xolair, aimed at treating nasal polyps; and AVT33, an oncology biosimilar. Established in 2013, Alvotech maintains its primary corporate headquarters in Reykjavik, Iceland.

        CEO
        Lisa Graver
        Employees
        1.46K
        Beta
        0.19

        Explore

        Frequently asked questions

        What is the intrinsic value of Alvotech (ALVO)?

        Alvotech (ALVO) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is ALVO undervalued?

        ALVO trades at a price of $4.12 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.